Prelude Capital Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Prelude Capital Management’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$101K	–	2085
2021 Q1	$101K	Buy	+10,000	New	+$99.9K	﹤0.01%	1427

Other funds holding EBACU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Prelude Capital Management's EBACU Position: Q2 2021 in Review

Prelude Capital Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q2 2021, closing a stake of 10,000 shares — an estimated $101K sold.

Prelude Capital Management first reported a position in EBACU in Q1 2021 and held it in 1 quarter. The position peaked at $101K in Q1 2021. 37 funds tracked by Wall St. Rank hold EBACU as of Q2 2021.

Prelude Capital Management reported no remaining European Biotech Acquisition Corp. Units position as of Q2 2021 after selling out during the quarter.
Prelude Capital Management sold 10,000 European Biotech Acquisition Corp. Units shares in Q2 2021, an estimated $101K.
Prelude Capital Management first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 1 quarter.
Prelude Capital Management's European Biotech Acquisition Corp. Units position peaked at $101K in Q1 2021.
37 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q2 2021.

Based on Prelude Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.